CJC-1295

CJC-1295 — Compare GHRH Analogs

CJC-1295 is a long-acting synthetic GHRH analog featuring Drug Affinity Complex (DAC) technology, engineered to sustain growth hormone pulse elevation through extended plasma activity and an approximately 8-day half-life that enables once-weekly subcutaneous administration [1]. Licensed practitioners who want to buy CJC-1295 can contact Medical Spa Rx’s professional support team for guidance on sourcing from qualified suppliers and for access to supporting documentation, including purity information. Browse this page to learn more about CJC-1295 and its research applications through the overview and FAQ sections below.

CJC-1295: Legal Status, Research Classification & DAC Technology

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) modified with Drug Affinity Complex (DAC) technology, allowing covalent albumin binding and extending its circulating half-life to approximately 8 days [1][3]. In research and practitioner-reported settings, it is commonly classified as a muscle growth and performance peptide due to its ability to amplify the amplitude and duration of endogenous growth hormone pulses through sustained pituitary stimulation [1][2]. Research discussions primarily focus on GH optimization, body composition, recovery protocols, and peptide therapy combinations involving selective GHRPs such as Ipamorelin.

Regulatory status as of mid 2026:

• United States: Not FDA-approved; not included on the 503A bulk substances compounding list; classified as a research compound only
• WADA: GH secretagogues are prohibited in-competition under the S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics); clinicians working with competitive athletes should advise them to review the current WADA Prohibited List before any protocol discussion involving CJC-1295
• Australia: Not TGA-approved; availability for compounding remains restricted under local regulatory frameworks
• Canada and EU: Similar restrictions may apply; jurisdiction-specific verification is essential before any procurement or research discussion

CJC-1295 with DAC vs. without DAC: Addressing the Naming Confusion

One of the most common points of confusion in the CJC 1295 peptide category is the distinction between CJC-1295 with DAC and CJC-1295 without DAC, also known as Modified GRF 1-29.

• CJC-1295 with DAC features an albumin-binding modification that extends its half-life to approximately 8 days, enabling once-weekly dosing [1].
• Modified GRF 1-29 lacks DAC technology, resulting in a half-life of approximately 30 minutes and requiring more frequent administration.

Although both target the same GHRH receptor, their pharmacokinetic differences produce substantially different GH release patterns and dosing schedules, and practitioners should not treat them as interchangeable.

How CJC-1295 Works: DAC Mechanism & Duration of Action

CJC-1295 binds to GHRH receptors on anterior pituitary somatotroph cells, stimulating endogenous GH synthesis and pulsatile release [1][2]. As a hormone-releasing hormone analog, it stimulates the body’s own GH secretion pathways rather than directly replacing them.

Key mechanistic features:

• DAC-mediated duration of action: A reactive lysine residue forms a covalent bond with circulating serum albumin, creating a depot-like effect that releases active peptide over approximately 8 days [1][3]; this contrasts with Sermorelin (~10–20 min half-life) and Tesamorelin (~26 min half-life) [5], making duration of action the defining differentiator
• Downstream GH/IGF-1 axis: GH stimulates hepatic IGF-1 production, which mediates anabolic activity, connective tissue support, recovery signaling, and lipolytic effects within adipose tissue [1]
• Preserved pulsatility: Practitioner-reported and early human data suggest research-referenced dosing does not suppress endogenous GHRH secretion, allowing physiological GH pulsatility to remain intact [2]
• Stable plasma concentrations: Once-weekly subcutaneous administration is the most commonly reported protocol; stable plasma levels are generally reached after approximately 2–3 weeks of continuous dosing [1]

CJC-1295 + Ipamorelin: Combination Protocol & Use Cases

The CJC-1295-Ipamorelin combination is the primary practitioner-reported use case for this compound and drives most interest in it. The pairing is based on complementary receptor systems rather than mechanistic overlap.

Why the Combination is Commonly Discussed

• CJC-1295 acts through the GHRH receptor: Increases GH pulse amplitude and prolongs secretion duration through sustained DAC-mediated pituitary stimulation [1][2]
• Ipamorelin acts through the ghrelin receptor (GHS-R): Initiates discrete GH pulses via a separate signaling pathway, producing additive rather than redundant effects [4]
• Ipamorelin is the preferred GHRP pairing: Unlike earlier-generation GHRPs, Ipamorelin does not significantly elevate cortisol or prolactin at research-referenced doses, reducing endocrine confounding variables in practitioner monitoring [4]

Practitioner-Reported Dosing Considerations (research-extrapolated; no RCT validation)

• CJC-1295 (DAC): Commonly referenced at 1–2 mg subcutaneously once weekly
• Ipamorelin: Frequently discussed at 100–300 mcg two to three times daily or prior to sleep
• Pre-sleep timing rationale: Evening administration is referenced because endogenous GH secretion naturally peaks during nocturnal sleep cycles

All CJC-1295 + Ipamorelin dosing should be understood as practitioner-reported and research-extrapolated. No controlled human RCT currently validates the efficacy or long-term safety of this specific combination protocol.

CJC-1295 for Muscle Growth, Body Composition & Recovery

Interest in CJC-1295 as a muscle growth and performance peptide is primarily linked to downstream IGF-1 elevation rather than any direct anabolic effect of the peptide itself [1]. Evidence tiers for reported applications are as follows:

• CJC-1295 for muscle growth (practitioner-reported / early human): Increased IGF-1 signaling supports lean mass accretion and muscle protein synthesis through established GH-related anabolic pathways [1]; not directly confirmed in large-scale controlled trials
• Fat oxidation and weight loss (practitioner-reported / extrapolated): GH-mediated lipolysis, particularly involving visceral adipose tissue, is commonly referenced; weight loss is discussed as a secondary benefit of sustained GH axis stimulation [1]
• Recovery support (practitioner-reported): Reduced inter-session recovery time, connective tissue support, and improved training tolerance are frequently cited in sports medicine and performance peptide discussions
• Sleep quality (practitioner-reported): Amplification of nocturnal GH pulses when CJC-1295 is paired with pre-sleep Ipamorelin dosing is commonly referenced as a quality-of-life benefit in anti-aging and performance protocols [2]

All outcome claims above remain primarily practitioner-reported and research-extrapolated. Clinicians should not present these as clinically established endpoints.

CJC-1295 Side Effects & Safety Profile

CJC-1295 side effects data are limited, with no large-scale human RCTs defining a long-term safety profile. Risk characterization is extrapolated from broader data on GHRH analogs, small early studies, and practitioner reports [1].

Commonly reported effects include:

• Water retention and mild edema: Attributed to IGF-1-mediated sodium retention; typically transient during initial weeks of dosing [1]
• Injection site reactions: Mild redness or swelling at the subcutaneous injection site; nonspecific to this compound class [1]
• Sustained IGF-1 elevation: Raises theoretical concerns regarding cell proliferation, particularly relevant for individuals with a personal or family history of hormone-sensitive conditions; this risk is not yet quantified in human trial data [1]

When evaluating whether CJC-1295 is safe for research use, clinicians should clearly communicate these evidence gaps and frame all safety discussions in the context of currently available data rather than in terms of established clinical safety standards.

CJC-1295 vs. Sermorelin

Both CJC-1295 and Sermorelin are synthetic GHRH analogs that stimulate anterior pituitary receptors, increasing endogenous growth hormone release, making their shared receptor class the starting point for any comparison [1]. The primary differentiator is duration of action: Sermorelin has a half-life of approximately 10–20 minutes and typically requires nightly administration to support GH pulsatility, whereas CJC-1295’s DAC modification extends circulating activity to roughly 8 days, enabling once-weekly dosing [1]. These pharmacokinetic differences significantly affect protocol design, injection frequency, and compliance considerations in discussions of peptide therapy.

Practitioners may favor Sermorelin when prioritizing a GH secretion pattern that more closely mirrors physiological pulsatility, given its short half-life, which allows the pituitary to return to baseline between doses [2]. CJC-1295 is more commonly discussed in protocols where reduced injection frequency and sustained GH elevation are priorities, such as body composition and performance-focused research settings [1]. Researchers who choose to buy Sermorelin for comparative protocol work will find its shorter half-life and daily dosing profile provide a useful physiological reference point alongside CJC-1295’s extended DAC-mediated activity.

CJC-1295 vs. Tesamorelin

CJC-1295 and Tesamorelin are both synthetic GHRH analogs but differ substantially in half-life, approval status, and clinical positioning. Tesamorelin carries an approximately 26-minute half-life and holds FDA approval for reducing excess abdominal fat in adults with HIV-associated lipodystrophy [5], giving it a defined regulatory, procurement, and indication framework. CJC-1295, by contrast, has an extended half-life of approximately 8 days through its DAC modification [1] and remains a research compound without an FDA-approved indication.

Tesamorelin is appropriate where a specific approved indication and its associated regulatory framework are required [5]. CJC-1295 is more frequently discussed in anti-aging, sports medicine, and GH optimization research contexts, where once-weekly administration and broader applications in body composition are the focus [1]. Researchers who choose to buy Tesamorelin for comparative protocol work will find that its FDA-approved indication for visceral fat reduction [5] and daily dosing requirements offer a distinct regulatory and mechanistic contrast to CJC-1295.

Where Can Practitioners Buy CJC-1295 Online?

CJC-1295 is a research-grade compound available for purchase by qualified professionals only and is not intended for personal, therapeutic, or clinical use. Practitioners looking to order CJC-1295 from a verified research-grade supplier should source only from vendors who can provide verifiable purity documentation, LOT number traceability, and a certificate of analysis for each batch. These standards are particularly important when buying online, where supplier transparency varies widely.

Medical Spa Rx’s professional support team offers sourcing guidance and documentation support to help licensed professionals identify qualified suppliers and evaluate wholesale buying options. Practitioners are encouraged to contact Medical Spa Rx’s professional support team directly for guidance and direction on supplier standards, documentation requirements, and research-grade sourcing considerations when looking to buy CJC-1295 wholesale.

FAQs

1. What is CJC-1295, and what does it do?

CJC-1295 is a long-acting synthetic GHRH analog modified with DAC technology, extending its half-life to approximately 8 days. It stimulates pituitary GHRH receptors, increasing endogenous growth hormone release and downstream IGF-1 production. Reported research applications include support for body composition, recovery, and GH optimization protocols. It is not FDA-approved and remains classified as a research compound as of mid 2026.

2. What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC binds albumin, extending its half-life to approximately 8 days and enabling once-weekly dosing. Without DAC (Modified GRF 1-29), the half-life is approximately 30 minutes, requiring more frequent administration. Both compounds act on the same GHRH receptor but generate substantially different GH release patterns; practitioners should clarify which form is being evaluated before comparing protocols.

3. Why is CJC-1295 combined with Ipamorelin?

CJC-1295 and Ipamorelin act on different receptors, making their effects complementary rather than redundant. CJC-1295 increases GH pulse amplitude and duration through GHRH receptor stimulation, while Ipamorelin triggers GH pulses via the ghrelin receptor. Ipamorelin’s selectivity, specifically its lack of cortisol or prolactin elevation at research doses, makes it the preferred GHRP partner. This combination is practitioner-reported and not validated in controlled human trials.

4. What are the CJC-1295 side effects — is it safe?

Commonly reported CJC-1295 side effects include mild water retention, transient edema, and local injection site reactions. Sustained elevation of IGF-1 raises theoretical concerns about cell proliferation in individuals with hormone-sensitive conditions. No large-scale human RCTs have defined the long-term safety profile, and the overall risk remains incompletely characterized. Clinicians should communicate these limitations clearly when discussing research protocols.

5. Is CJC-1295 legal — what is its WADA status?

As of mid 2026, CJC-1295 is not FDA-approved and is classified as a research compound in the United States; it is not on the 503A bulk substances compounding list. Under WADA rules, GH secretagogues are prohibited in-competition under the S2 category. Competitive athletes should review the current WADA Prohibited List independently before engaging in any discussion of CJC-1295 or related GHRH analogs.

Sources

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi:10.1210/jc.2006-1702
3. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1290-E1294. doi:10.1152/ajpendo.00201.2006
4. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
5. Traynor K. FDA approves tesamorelin for HIV-related lipodystrophy. Am J Health Syst Pharm. 2010;67(24):2082. doi:10.2146/news100082

The page and all of its displayed contents are for medical professionals, designed to inform only, and not as a replacement for medical advice.